Northwestern University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Northwestern University sits in the top decile of US sponsors by registered trial count (#23 of 15,742 sponsors by registered trial count).

1,209 total trials 187 currently recruiting 767 completed early-phase tilt top decile by trial count

Northwestern University: 1,209 sponsored US clinical trials, 187 recruiting.

Northwestern University sponsors 1,209 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 767 completed. 114 of these trials are in Phase 3-4 (later-stage) and 295 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 11 trials.

Top-decile sponsor footprint

Northwestern University ranks in the top decile of sponsors by registered trial count (#23 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 50/100

767 of 912 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,209 total, page 21 of 25

COMPLETED NA

Outreach for Patients With Uncompleted Colorectal Cancer Screening Orders

NCT00793455

COMPLETED NA

Tadalafil for the Treatment of Raynaud's

NCT00822354

TERMINATED NA

Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL

NCT00724061

COMPLETED NA

The Missouri Health Literacy and Diabetes Communication Initiative

NCT00973830

COMPLETED NA

Modification of Asthma With Soy Isoflavone

NCT00741208

TERMINATED Phase 4

Postpartum Depression: Transdermal Estradiol Versus Sertraline

NCT00744328

COMPLETED

Classification of Heart Failure With Preserved Ejection Fraction

NCT01030991

COMPLETED

The Differential Effects of 3 Different Immunosuppressive

NCT00729248

TERMINATED NA

Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

NCT00727532

TERMINATED Phase 3

PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)

NCT00729365

COMPLETED Phase 3

Effectiveness of Group Walking Sessions for Increasing Activity in People With Peripheral Arterial Disease (The Group Oriented Arterial Leg Study [GOALS])

NCT00693940

TERMINATED NA

Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism

NCT00745030

TERMINATED Phase 2

Sorafenib-induced Hand- Foot Skin Reaction Treatment

NCT00667589

COMPLETED NA

Study of Two Different 10.0% Benzoyl Peroxide Creams for Mild to Moderate Acne Vulgaris

NCT00787943

COMPLETED

Basal Cell Carcinoma Recurrence After Mohs Surgery

NCT00882791

TERMINATED NA

Women With Chest Pain and Normal Coronary Arteries Study

NCT00743197

COMPLETED

Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors

NCT00709878

COMPLETED Phase 2

Parkinson's Disease Isradipine Safety Study

NCT00753636

COMPLETED

Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer

NCT00739167

COMPLETED NA

Primary Care Community Partnerships to Prevent Diabetes

NCT00656682

TERMINATED Phase 1

A Novel Treatment for Metastatic Melanoma

NCT00758797

COMPLETED Phase 4

High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone

NCT00539071

TERMINATED Phase 3

Ramelteon for Insomnia Comorbid With Asthma

NCT00869167

COMPLETED NA

Comparison of Two Salicylic Acid Formulations

NCT00848744

TERMINATED

An In-vitro Standardization of B Cell Elispot Assays

NCT01334281

COMPLETED NA

HLA-Identical Sibling Renal Transplant Tolerance

NCT00619528

COMPLETED Phase 3

Effectiveness of Telephone Versus Face-to-Face CBT in Treating People With Depression

NCT00498706

COMPLETED

Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib

NCT00602433

COMPLETED NA

Effect of the Subconscious on Mohs Micrographic Surgery

NCT00374062

COMPLETED

Examining How Heart Disease Risk Factors Affect Healthy Aging (The Chicago Healthy Aging Study [CHAS])

NCT00626379

COMPLETED NA

Light Therapy Treatment in Parkinson's Disease Patients With Daytime Somnolence

NCT01338649

COMPLETED NA

Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris

NCT00558831

COMPLETED

Magnetic Resonance Imaging to Identify Characteristics of Plaque Build-Up in People With Peripheral Arterial Disease

NCT00520312

COMPLETED

Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents

NCT01678937

COMPLETED

Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery

NCT00793169

COMPLETED NA

Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients

NCT01127737

TERMINATED NA

The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes

NCT00787176

COMPLETED NA

A Photodynamic Therapy for Treatment of Actinic Keratoses

NCT00558688

COMPLETED

Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels

NCT01014754

TERMINATED Phase 1

VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma

NCT00516282

TERMINATED Phase 1

Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

NCT00372905

COMPLETED NA

Ulcerative Colitis Relapse Prevention Trial, Hypnosis

NCT00798642

COMPLETED

Bone Loss, Fractures, and Management of Bone Health in People With Stroke in Managed Rehabilitation Settings

NCT00462683

COMPLETED Phase 2

Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events

NCT01586975

COMPLETED

Genetic Predisposition-Chronic Nephrotoxicity From CI-Liver Transplant Recipients-Potential Correlation-Urinary Biomarkers

NCT00857844

COMPLETED Phase 4

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

NCT00866879

COMPLETED NA

Treatment of Acne Scarring With a Novel Procedure Combination

NCT00510055

COMPLETED Phase 4

Improving Prescription Drug Warning Labels

NCT00846209

COMPLETED NA

Non-prescription Versus Prescription Topical Treatments Versus no Treatment in the Control of Sweating

NCT00509886

COMPLETED NA

Study of Acid Peel and Laser for the Treatment of Melasma

NCT00467233

← Previous Page 21 of 25 Next →

Phase Distribution

PhaseTrial count
Phase 1 132
Phase 2 163
Phase 3 36
Phase 4 78

What is open in the Northwestern University pipeline

187 recruiting of 1,209 indexed (15% open); 767 completed (63%).

Phase mix: 114 late (III/IV) vs 295 early (I/II) (early-phase heavy).

Top condition: Depression (11 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Northwestern University: open-pipeline peers nationwide

Peers matched on 1,209 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Northwestern University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 12%14%16%18%20% Total trials Recruiting share Northwestern UniversityEmory UniversityUniversity of PittsburghNYU Langone HealthUniversity of Alabama at BirminghamBrigham and Women's HospitalIncyte CorporationNationwide Children's HospitalUniversity of Michigan Rogel Cancer Center
Northwestern University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Northwestern University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,209 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this Northwestern University page

1,209 registered trials is a research-attention snapshot, not an endorsement of Northwestern University or any single study.

  • 187 of Northwestern University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition Northwestern University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Northwestern University pipeline card: 1,209 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.